Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis

Abstract Aims We sought to conduct a meta‐analysis regarding the safety and efficacy of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results MEDLINE, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov were searched from their inception to November...

Full description

Bibliographic Details
Main Authors:	Javed Butler, Muhammad Shariq Usman, Muhammad Shahzeb Khan, Stephen J. Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos Filippatos, Andrew J. Stewart Coats, Stefan D. Anker
Format:	Article
Language:	English
Published:	Wiley 2020-12-01
Series:	ESC Heart Failure
Online Access:	https://doi.org/10.1002/ehf2.13169

Similar Items

Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis
by: Muhammad Shahzeb Khan, et al.
Published: (2021-06-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2019-11-01)

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
by: Muhammad Shahzeb Khan, et al.
Published: (2021-02-01)

Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
by: Subodh Verma, et al.
Published: (2020-12-01)

Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis
by: Muhammad Shahzeb Khan, et al.
Published: (2020-12-01)

Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
by: Muhammad Shahzeb Khan, et al.
Published: (2021-02-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
by: Natalia G. Vallianou, et al.
Published: (2021-06-01)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
by: Aggarwal, R., et al.
Published: (2022)

Sodium–glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction
by: Adamo, M., et al.
Published: (2022)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
by: Giuseppe Palmiero, et al.
Published: (2021-05-01)

SGLT2 Inhibitor–Induced Sympathoinhibition
by: Lakshini Y. Herat, PhD, et al.
Published: (2020-02-01)

Renoprotective Effects of SGLT2 Inhibitors
by: Guja Cristian, et al.
Published: (2019-06-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis
by: Vasiliki Tsampasian, et al.
Published: (2021-01-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial
by: Muhammad Shahzeb Khan, et al.
Published: (2021-04-01)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor drugs: Assessment of safety in Fasting Diabetics
by: Muhammad Imran Hasan Khan, et al.
Published: (2021-03-01)

Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function
by: Carsten Tschöpe, et al.
Published: (2020-12-01)

Heart failure guidelines implementation: Lifting barriers using registries and networks
by: Kalliopi Keramida, et al.
Published: (2020-07-01)

Vitamin B12 deficiency in heart failure: another “brick in the wall”
by: Vasiliki Bistola, et al.
Published: (2020-09-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

SGLT-2 inhibitors and their potential in the treatment of diabetes
by: Rosenwasser RF, et al.
Published: (2013-11-01)

Recommendations on the Proper Use of SGLT2 Inhibitors
by: The Committee on the Proper Use of SGLT2 Inhibitors
Published: (2020-01-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
by: Gloria M. Gager, et al.
Published: (2021-07-01)

Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
by: Gloria M. Gager, et al.
Published: (2021-11-01)

SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
by: José Silva-Cardoso, et al.
Published: (2021-09-01)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
by: Qasim Zafar Iqbal, et al.
Published: (2020-01-01)

SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
by: Yasuhiro Maejima
Published: (2020-01-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
by: Francisco Castaneda, Antje Burse, Wilhelm Boland, Rolf K-H. Kinne
Published: (2007-01-01)

SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
by: Ying Zhou, et al.
Published: (2019-01-01)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018-02-01)

Role of SGLT2 inhibitors in the treatment of visceral obesity
by: M. A. Druzhilov, et al.
Published: (2021-02-01)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
by: Wenjun Sha, et al.
Published: (2020-01-01)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
by: Yi-Chou Hou, et al.
Published: (2020-10-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
by: Aaron Y. Kluger, et al.
Published: (2019-08-01)

Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
by: Coralea Kappel
Published: (2019-12-01)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
by: Carlo Garofalo, et al.
Published: (2019-06-01)